Metabolic bariatric surgery as a therapeutic option for patients with type 2 diabetes: A meta‐analysis and network meta‐analysis of randomized controlled trials
Authors' conclusion
MBS is an effective option for the treatment of T2D in patients with obesity. Further long-term trials of appropriate quality are needed for assessing the risk-benefit ratio in some patient cohorts, such as those with a BMI of less than 35 kg/m2 and aged older than 65 years.
Study context
- Population
- Patients with T2D in RCTs (duration ≥ 52 weeks)36 trials
- Comparison
- Metabolic bariatric surgery vs non-surgical therapy
- Outcome
- Endpoint HbA1c, BMI and diabetes remission
Methodological detailsRCTs with duration ≥ 52 weeks
- RCTs with duration ≥ 52 weeks
Pooled result
As reported in the abstract
HbA1c, diabetes remission and BMI
- Metabolic bariatric surgery (MBS) associated with significantly higher reduction of HbA1c, diabetes remission and body mass index (BMI) vs medical therapy
- Network meta-analysis (NMA): significant HbA1c reduction with one-anastomosis gastric bypass (OAGB) and sleeve gastrectomy (SG)
- NMA: complete diabetes remission significantly increased with all surgical procedures vs non-surgical therapy, except greater curvature plication (GCP)
- NMA: only bilio-pancreatic diversion (BPD), RYGB and OAGB associated with significant BMI reduction
Original publication
Metabolic bariatric surgery as a therapeutic option for patients with type 2 diabetes: A meta‐analysis and network meta‐analysis of randomized controlled trials. Diabetes Obes Metab. Published 5 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →